<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />


<meta name="author" content="AKI Safety Working Group" />

<meta name="date" content="2025-04-30" />

<title>Step 1 – Causal Question, Causal Model, and Causal Estimand</title>

<script src="site_libs/header-attrs-2.29/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">HOME</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="RWE_tutorial.html">Introduction: TL Roadmap in RWE</a>
</li>
<li>
  <a href="case_study_AKI.html">Case study intro: Hep. C and AKI</a>
</li>
<li>
  <a href="roadmapV2.html">Case study Roadmap in RWE</a>
</li>
<li>
  <a href="PS_analysis.html">Propensity score matching analysis</a>
</li>
<li>
  <a href="TMLE_analysis.html">Targeted learning analysis</a>
</li>
<li>
  <a href="results_comparisons.html">Analysis comparisons</a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Step 1 – Causal Question, Causal Model, and
Causal Estimand</h1>
<h4 class="author">AKI Safety Working Group</h4>
<h4 class="date">2025-04-30</h4>

</div>


<div id="scientific-question" class="section level1" number="1">
<h1><span class="header-section-number">1</span> 1 Scientific
Question</h1>
<blockquote>
<p><em>Among U.S. adults with chronic hepatitis C (HCV) who initiate
antiviral therapy, does starting a
<strong>sofosbuvir-containing</strong> direct-acting antiviral (DAA)
regimen, compared with starting a <strong>non-sofosbuvir</strong> DAA
regimen, change the 90-day cumulative risk of first acute kidney injury
(AKI)?</em></p>
</blockquote>
<p><strong>Study setting</strong></p>
<ul>
<li><strong>Population</strong> – commercial &amp; Medicare Advantage
enrollees, 18–79 y, ≥12 m continuous coverage, no baseline AKI, chronic
HCV.<br />
</li>
<li><strong>Treatment strategies</strong>
<ul>
<li><em>A = 1</em>: initiate any SOF-containing DAA regimen<br />
</li>
<li><em>A = 0</em>: initiate any non-SOF DAA regimen (G/P, EBR/GZR,
OMB/PTV/r±DAS, …)<br />
</li>
</ul></li>
<li><strong>Outcome Y</strong> – first AKI claim / EHR record within 90
days.<br />
</li>
<li><strong>Intercurrent events</strong> – regimen switch, death,
disenrollment.<br />
</li>
<li><strong>Summary measure</strong> – marginal risk difference (RD) and
risk ratio (RR) at 90 days.</li>
</ul>
</div>
<div id="causal-model-informal-dag" class="section level1" number="2">
<h1><span class="header-section-number">2</span> 2 Causal Model
(informal DAG)</h1>
<p>W ─▶ A0 ─▶ Y(90d) │ │ ▲ │ └──────────────┘ └────────────▶</p>
<ul>
<li><strong>W</strong> – baseline confounders (age, sex, CKD, diabetes,
eGFR, cirrhosis, utilisation, …)<br />
</li>
<li><strong>A0</strong> – initial regimen choice at time 0<br />
</li>
<li><strong>C(t)</strong> – censoring: death, switch, loss of
coverage<br />
</li>
<li><strong>Y(t)</strong> – indicator of AKI by day <em>t</em></li>
</ul>
<p>Assumed for identification:</p>
<ol style="list-style-type: decimal">
<li><em>Consistency</em><br />
</li>
<li><em>Positivity</em>: 0 &lt; P(A0 = a |W) &lt; 1<br />
</li>
<li><em>Conditional exchangeability</em>: no unmeasured common causes of
<em>(A0, C(t))</em> and <em>Y(t)</em> given <em>W</em>.</li>
</ol>
</div>
<div id="target-estimands" class="section level1" number="3">
<h1><span class="header-section-number">3</span> 3 Target Estimands</h1>
<p>The AKI study used an <strong>as-treated, censor-at-switch</strong>
estimand (★).<br />
Alternative estimands answer related questions or relax assumptions.</p>
<table>
<colgroup>
<col width="20%" />
<col width="20%" />
<col width="20%" />
<col width="20%" />
<col width="20%" />
</colgroup>
<thead>
<tr class="header">
<th>Label</th>
<th>Strategy for switch / death</th>
<th>90-day target</th>
<th>Question addressed</th>
<th>Identification caveats</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>★ As-treated (censor at switch)</strong></td>
<td>Censor follow-up 30 d after switch; admin censoring for
death/loss</td>
<td>RD / RR if everyone <strong>remains on their original
regimen</strong></td>
<td>Effect of staying on initial therapy</td>
<td>Requires ignorability of censoring given <em>W, A0</em> (+
time-varying covariates if used)</td>
</tr>
<tr class="even">
<td>ITT (ignore switch)</td>
<td>Keep follow-up regardless of switch</td>
<td>RD / RR for <strong>initiation</strong> of SOF vs non-SOF</td>
<td>Policy effect of starting SOF</td>
<td>No informative censoring; effect diluted by cross-over</td>
</tr>
<tr class="odd">
<td>Per-protocol (model switch)</td>
<td>Treat switch as time-varying exposure; g-formula / MSM</td>
<td>Risk if everyone <strong>remained</strong> on assigned therapy</td>
<td>Pure biologic effect</td>
<td>Requires measurement &amp; modelling of time-varying confounders and
switching process</td>
</tr>
<tr class="even">
<td>Hypothetical “no-switch”</td>
<td>Censor at switch <strong>and</strong> weight by inverse probability
of switching</td>
<td>Risk had switching been prevented</td>
<td>Safety absent regimen changes</td>
<td>Correct model for switching hazard necessary</td>
</tr>
<tr class="odd">
<td>Composite (AKI <em>or</em> switch)</td>
<td>Count switch as event</td>
<td>RD / RR for <strong>AKI or regimen change</strong></td>
<td>Captures clinical concern that switch may signal renal toxicity</td>
<td>Blurs pathways; easier for decision-making</td>
</tr>
<tr class="even">
<td>Controlled direct effect</td>
<td>Treat death as competing risk (censor)</td>
<td>AKI risk if death eliminated</td>
<td>Kidney toxicity independent of mortality</td>
<td>Counterfactual elimination of death; strong &amp; possibly
implausible</td>
</tr>
</tbody>
</table>
<div id="choosing-among-estimands" class="section level2" number="3.1">
<h2><span class="header-section-number">3.1</span> Choosing among
estimands</h2>
<ul>
<li><strong>Regulatory safety signal</strong> – ★ As-treated is
customary: isolates renal risk during exposure; beware informative
switching.<br />
</li>
<li><strong>Clinical decision (“start vs do not start”)</strong> – ITT
may be preferable.<br />
</li>
<li><strong>Mechanistic/toxicology</strong> – hypothetical or
per-protocol estimands focus on inherent nephro-toxicity.</li>
</ul>
<p>Subsequent Roadmap steps (identification, estimation, sensitivity)
must align with the chosen estimand.</p>
</div>
</div>
<div id="place-holder-for-code" class="section level1" number="4">
<h1><span class="header-section-number">4</span> 4 Place-holder for
Code</h1>
<ul>
<li><strong>W</strong> – baseline confounders (age, sex, CKD, diabetes,
eGFR, cirrhosis, utilisation, …)<br />
</li>
<li><strong>A0</strong> – initial regimen choice at time 0<br />
</li>
<li><strong>C(t)</strong> – censoring: death, switch, loss of
coverage<br />
</li>
<li><strong>Y(t)</strong> – indicator of AKI by day <em>t</em></li>
</ul>
<p>Assumed for identification:</p>
<ol style="list-style-type: decimal">
<li><em>Consistency</em><br />
</li>
<li><em>Positivity</em>: 0 &lt; P(A0 = a |W) &lt; 1<br />
</li>
<li><em>Conditional exchangeability</em>: no unmeasured common causes of
<em>(A0, C(t))</em> and <em>Y(t)</em> given <em>W</em>.</li>
</ol>
</div>
<div id="target-estimands-1" class="section level1" number="5">
<h1><span class="header-section-number">5</span> 3 Target Estimands</h1>
<p>The AKI study used an <strong>as-treated, censor-at-switch</strong>
estimand (★).<br />
Alternative estimands answer related questions or relax assumptions.</p>
<table>
<colgroup>
<col width="20%" />
<col width="20%" />
<col width="20%" />
<col width="20%" />
<col width="20%" />
</colgroup>
<thead>
<tr class="header">
<th>Label</th>
<th>Strategy for switch or death</th>
<th>90-day target</th>
<th>Question addressed</th>
<th>Identification caveats</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>★ As-treated (censor at switch)</strong></td>
<td>Censor follow-up 30 d after switch; admin censoring for
death/loss</td>
<td>RD / RR if everyone <strong>remains on their original
regimen</strong></td>
<td>Effect of staying on initial therapy</td>
<td>Requires ignorability of censoring given <em>W, A0</em> (+
time-varying covariates if used)</td>
</tr>
<tr class="even">
<td>ITT (ignore switch)</td>
<td>Keep follow-up regardless of switch</td>
<td>RD / RR for <strong>initiation</strong> of SOF vs non-SOF</td>
<td>Policy effect of starting SOF</td>
<td>No informative censoring; effect diluted by cross-over</td>
</tr>
<tr class="odd">
<td>Per-protocol (model switch)</td>
<td>Treat switch as time-varying exposure; g-formula / MSM</td>
<td>Risk if everyone <strong>remained</strong> on assigned therapy</td>
<td>Pure biologic effect</td>
<td>Requires measurement &amp; modelling of time-varying confounders and
switching process</td>
</tr>
<tr class="even">
<td>Hypothetical “no-switch”</td>
<td>Censor at switch <strong>and</strong> weight by inverse probability
of switching</td>
<td>Risk had switching been prevented</td>
<td>Safety absent regimen changes</td>
<td>Correct model for switching hazard necessary</td>
</tr>
<tr class="odd">
<td>Composite (AKI <em>or</em> switch)</td>
<td>Count switch as event</td>
<td>RD / RR for <strong>AKI or regimen change</strong></td>
<td>Captures clinical concern that switch may signal renal toxicity</td>
<td>Blurs pathways; easier for decision-making</td>
</tr>
<tr class="even">
<td>Controlled direct effect</td>
<td>Treat death as competing risk (censor)</td>
<td>AKI risk if death eliminated</td>
<td>Kidney toxicity independent of mortality</td>
<td>Counterfactual elimination of death; strong &amp; possibly
implausible</td>
</tr>
</tbody>
</table>
<div id="choosing-among-estimands-1" class="section level2"
number="5.1">
<h2><span class="header-section-number">5.1</span> Choosing among
estimands</h2>
<ul>
<li><strong>Regulatory safety signal</strong> – ★ As-treated is
customary: isolates renal risk during exposure; beware informative
switching.<br />
</li>
<li><strong>Clinical decision (“start vs do not start”)</strong> – ITT
may be preferable.<br />
</li>
<li><strong>Mechanistic/toxicology</strong> – hypothetical or
per-protocol estimands focus on inherent nephro-toxicity.</li>
</ul>
<p>Subsequent Roadmap steps (identification, estimation, sensitivity)
must align with the chosen estimand.</p>
</div>
<div id="causal-model-ggdag-plot" class="section level2" number="5.2">
<h2><span class="header-section-number">5.2</span> 2 Causal Model –
ggdag plot</h2>
<pre class="r"><code>library(tidyverse) </code></pre>
<pre><code>## ── Attaching core tidyverse packages ──────────────────────── tidyverse 2.0.0 ──
## ✔ dplyr     1.1.4     ✔ readr     2.1.5
## ✔ forcats   1.0.0     ✔ stringr   1.5.1
## ✔ ggplot2   3.5.1     ✔ tibble    3.2.1
## ✔ lubridate 1.9.3     ✔ tidyr     1.3.1
## ✔ purrr     1.0.2     
## ── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──
## ✖ dplyr::filter() masks stats::filter()
## ✖ dplyr::lag()    masks stats::lag()
## ℹ Use the conflicted package (&lt;http://conflicted.r-lib.org/&gt;) to force all conflicts to become errors</code></pre>
<pre class="r"><code>library(dagitty) </code></pre>
<pre><code>## Warning: package &#39;dagitty&#39; was built under R version 4.4.3</code></pre>
<pre class="r"><code>library(ggdag)</code></pre>
<pre><code>## Warning: package &#39;ggdag&#39; was built under R version 4.4.3</code></pre>
<pre><code>## 
## Attaching package: &#39;ggdag&#39;
## 
## The following object is masked from &#39;package:stats&#39;:
## 
##     filter</code></pre>
<pre class="r"><code># DAG specification -------------------------------------------------------
#   W  = baseline confounders
#   A0 = initial DAA regimen (SOF vs non-SOF)
#   C  = censoring processes (death, switch, disenroll)
#   Y  = 90-day AKI

dag_txt &lt;- &quot;
dag {
  W  -&gt; A0
  W  -&gt; Y
  A0 -&gt; Y
  W  -&gt; C
  A0 -&gt; C
}&quot;

aki_dag &lt;- dagitty(dag_txt)

# Visualise ---------------------------------------------------------------
ggdag(aki_dag, text = FALSE, use_labels = &#39;name&#39;, seed = 123) +
  theme_dag() +
  ggtitle(&#39;AKI Safety DAG: Sofosbuvir vs Non-Sofosbuvir&#39;)</code></pre>
<p><img src="step1_files/figure-html/unnamed-chunk-1-1.png" width="672" /></p>
</div>
</div>
<div id="step-1-defining-the-causal-question-model-and-estimands"
class="section level1" number="6">
<h1><span class="header-section-number">6</span> Step 1 — Defining the
Causal Question, Model, and Estimands</h1>
<p>In the causal inference roadmap, clearly defining the scientific
question, causal model, and target estimands is critical for valid
analysis and interpretability. This first step sets the foundation for
the entire analysis. ## 1.1 Defining the Causal Question The first step
in the causal roadmap involves translating a clinical or regulatory
question into a clearly defined causal question. A well-formulated
causal question clearly identifies the target population, interventions
(or exposures), and outcomes of interest. <strong>Example:</strong> &gt;
<em>Among U.S. adults diagnosed with chronic hepatitis C virus (HCV) who
initiate antiviral therapy, what is the effect of initiating a
<strong>sofosbuvir-containing direct-acting antiviral (DAA)
regimen</strong> compared to initiating a <strong>non-sofosbuvir DAA
regimen</strong> on the 90-day cumulative risk of experiencing acute
kidney injury (AKI)?</em> This question explicitly identifies: -
<strong>Target population:</strong> Adults aged 18–79 with chronic HCV,
continuously enrolled for ≥12 months. - <strong>Interventions:</strong>
Initiation of SOF-containing regimen versus non-SOF regimen. -
<strong>Outcome:</strong> AKI occurrence within 90 days. This clarity
ensures all subsequent steps in the roadmap remain aligned with the
original scientific intent. ## 1.2 Specifying the Causal Model (DAG)
Causal inference typically involves representing relationships between
variables visually using directed acyclic graphs (DAGs). A DAG helps
clarify the assumptions necessary for valid causal inference,
particularly: - <strong>Exchangeability (no unmeasured
confounding)</strong> - <strong>Positivity (treatment assignment
possible across covariates)</strong> - <strong>Consistency (treatment
definitions correspond to reality)</strong> Consider the following
simplified DAG illustrating relationships in our AKI study:</p>
<p><strong>Explanation of DAG components:</strong> - <strong>W (Baseline
Covariates):</strong> Factors like age, sex, baseline kidney function,
diabetes, liver cirrhosis, healthcare utilization. These influence both
treatment selection (A) and AKI outcome (Y). - <strong>A
(Treatment):</strong> Initial choice between SOF-containing or
non-SOF-containing DAAs. - <strong>Y (Outcome):</strong> AKI event
within 90 days after treatment initiation. - <strong>C (Censoring
events):</strong> Events that lead to incomplete follow-up, such as
death, regimen switching, or loss of insurance. The DAG explicitly
assumes no direct arrows from unknown or unmeasured variables to A and Y
(conditional on W), reflecting the key assumption of conditional
exchangeability. ## 1.3 Defining Causal Estimands An
<strong>estimand</strong> is a precisely defined causal parameter
representing what we aim to estimate. The International Council for
Harmonisation (ICH) guideline E9(R1) highlights the importance of
clearly defining estimands in clinical trials and real-world studies to
ensure clarity about the causal effects being studied. Different ways of
handling intercurrent events—such as treatment switching—lead to
different estimands, each with distinct interpretations. Clearly
specifying the estimand upfront is crucial for study validity. ###
Common Estimand Choices We summarize several common estimands below,
indicating clearly which was selected as the primary in the original AKI
analysis (<strong>marked ★</strong>):</p>
<table>
<colgroup>
<col width="7%" />
<col width="38%" />
<col width="17%" />
<col width="20%" />
<col width="17%" />
</colgroup>
<thead>
<tr class="header">
<th>Label</th>
<th>How are intercurrent events handled?</th>
<th>Target (90-day)</th>
<th>Scientific meaning</th>
<th>Key assumptions</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>^As-treated</strong></td>
<td>Censor follow-up after regimen switch (30-day wash-out), death,
loss</td>
<td>Risk if patients adhered to initial regimen (RD/RR)</td>
<td>Direct toxicity of regimen while taken</td>
<td>Non-informative censoring (no unmeasured predictors of
switching)</td>
</tr>
<tr class="even">
<td>ITT (Treatment Policy)</td>
<td>Ignore switching events, follow regardless</td>
<td>Risk for initial treatment assignment (RD/RR)</td>
<td>Real-world policy decision: start SOF vs not</td>
<td>Switching dilutes effect; requires no assumption about
censoring</td>
</tr>
<tr class="odd">
<td>Per-protocol</td>
<td>Model switching explicitly (time-varying exposure), adjust via
weighting/g-formula</td>
<td>Risk if all remained on assigned treatment</td>
<td>“Biological” toxicity unaffected by treatment changes</td>
<td>Needs correctly specified time-dependent exposure/confounder
models</td>
</tr>
<tr class="even">
<td>Composite endpoint</td>
<td>Include regimen switch as outcome event</td>
<td>Combined risk of AKI or treatment change</td>
<td>Practical endpoint capturing clinical action driven by renal
issues</td>
<td>Blurs biological and clinical decision-making pathways</td>
</tr>
<tr class="odd">
<td>Controlled Direct Effect</td>
<td>Treat death as competing event</td>
<td>AKI risk if death eliminated</td>
<td>Toxicity independent of mortality</td>
<td>Counterfactual scenario (removing death) potentially
unrealistic</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr class="header">
<th>Roadmap Component</th>
<th>Section Covered</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Question definition</strong></td>
<td>Section 1.1</td>
</tr>
<tr class="even">
<td><strong>Causal Model (DAG)</strong></td>
<td>Section 1.2</td>
</tr>
<tr class="odd">
<td><strong>Estimand definition</strong></td>
<td>Section 1.3, Table</td>
</tr>
<tr class="even">
<td><strong>Choice of primary estimand</strong></td>
<td>Section 1.4</td>
</tr>
</tbody>
</table>
<p><strong>Next Steps:</strong> Subsequent chapters will detail
identification assumptions, estimation procedures (TMLE, Super Learner),
sensitivity analyses, and interpretation strategies in alignment with
this foundational framework. —</p>
<div id="references" class="section level3" number="6.0.1">
<h3><span class="header-section-number">6.0.1</span> References</h3>
<p>Dang et al. (2023). JCTS. Rufibach (2019). Pharmaceutical Statistics.
Stensrud et al. (2019). Eur Heart J. Martinussen (2022). Ann Rev Stat
Appl.</p>
</div>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
